CDKN2A and oropharynx cancer: The p16 immunohistochemical expression was found in 7 (18.4%) of 38 cases of oral-oropharyngeal cancers, particularly 3 cases p16-positive (7.9%) showed high expression, 2 cases (5.3%) moderate expression and 2 cases (5.3%) low expression.